SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published inStrokeentitled "Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke." Co-authors include Michael L. Levy, MD, PhD, John R. Crawford, MD, Nabil Dib, MD, Lev Verkh, PhD, Nikolai Tankovich, MD, PhD and Steven C. Cramer, MD.
As indicated in theStrokepublication, "Stroke is perennially among the leading causes of human disability and the leading neurological cause of lost disability-adjusted life years. The mean survival after stroke is 6-7 years, with more than 85% of patients living past the first-year post-stroke, many with years of enduring disability. Many restorative therapies are under study to improve outcomes after stroke." However, restorative therapies often have a short time window for improvement usually measured in days-months.
"Based on Stemedica's preclinical data that supported the safety and efficacy of its MSCs as a restorative therapy to improve outcomes after stroke, the company was granted approval by the FDA to conduct a Phase I/IIa dose escalation trial that examined the effects of a single IV infusion of Stemedica's cGMP manufactured allogeneic ischemia-tolerant MSCs," said Dr. Lev Verkh, Chief Regulatory and Clinical Development Officer of Stemedica.
Study:The target population included patients with chronic ischemic stroke and substantial functional deficits; a group for whom treatment options remained limited. The primary outcome of the study was safety, based on serial measures of behavior, CT scans, and laboratory testing. Four secondary endpoints were scored serially to derive estimates of behavioral changes relatively to the baseline over a period of 12 months: NIH Stroke Scale (NIHSS) for neurological assessment, Barthel Index (BI) for ability to perform daily tasks, Mini-Mental Status Exam (MMSE) for mental status, and Geriatric Depression Scale (GDS) for degree of depression. The study was conducted at three centers: University of California, San Diego (UCSD); Mercy Gilbert Medical Center, Gilbert, Arizona; and University of California, Irvine (UCI).
Entry criteria included ischemic stroke >6 months prior to administration, substantial functional deficits (subject confined to a wheelchair, had home-nursingcare, orneeded assistance withactivities ofdailyliving), no substantial improvement in neurologic orfunctional deficits for the2 months prior to enrollment in thestudypermedical history, and NIHSS score=6-20.
Enrollees received a single intravenous dose of allogeneic mesenchymal bone marrow cells. Phase I used a dose escalation design (3 tiers, n=5 each). Phase IIa (n=21) was an expanded safety cohort. The primary endpoint was safety over 1-year. Secondary endpoints examined behavior, with a pre-specified focus at 6-months.
Subject status at enrollment prior to treatment:At baseline, subjects (n=36) averaged 4.24.6 years post-stroke, age 61.110.8 years, NIHSS score 8 [6.5-10], and Barthel Index 6529.
Safety:Study testing disclosed no safety concerns. No subject showed a positive reaction to intradermal testing. In Phase I, each dose (0.5, 1.0, and 1.5 million cells/kg body weight) was found safe, as a result Phase IIa subjects received 1.5 million cells/kg. Two subjects were lost to follow-up, one was withdrawn, and two died (unrelated to study treatment). There were 15 serious adverse events, none possibly or probably related to study treatment. Two mild adverse events were possibly related to study treatment, a urinary tract infection and IV site irritation. Treatment was determined to be safe based on serial exams, EKGs, laboratory tests, and pan-CT scans.
Behavioral Effects:Improvements across all subjects post-transfusion and for all four secondary endpoints were achieved. Improvements in each index were: Barthel Index (6.811.4 points, p=0.002); in NIHSS (-1.251.7 points, p<0.001); Mini Mental Status Exam (1.82.8 points, p<0.001); and Geriatric Depression Scale (-1.63.8 points, p=0.015). At baseline 11.4% (4/35 subjects) had Barthel Index=95-100 (favorable outcome); at 6-months, 27.3% (9/33); by 12-months, 35.5% (11/31).
Conclusions:The current study is the largest trial of intravenous MSCs in patients with chronic stroke and the first to evaluate allogeneic MSC therapy in this population. It is also the first study to evaluate MSCs grown under hypoxic conditions favorable to cell proliferation, gene expression, cytokine production and migration. While patients with stroke in the chronic stage generally show significant functional decline, enrollees in the current study showed 12 months of continued functional improvements across all secondary endpoints.
Intravenous transfusion of allogeneic ischemia tolerant MSCs in patients with chronic stroke and substantial functional deficits was safe and suggested behavioral gains. These data support proceeding to a randomized, placebo-controlled study of this therapy in this population.
Dr. Nikolai Tankovich, President and Chief Medical Officer added, "Stemedica is encouraged by the results of the study which demonstrated safety and preliminary efficacy of its cell therapy product for the treatment of chronic ischemic stroke patients. It is a significant milestone for Stemedica to bring this new cellular medication to patients with debilitating conditions caused by a stroke. Stemedica plans to move forward to a Phase-IIb discussion with the FDA."
Michael Levy, MD, PhD, FACS, FAANS, Professor of Neurosurgery at UCSD and the Principal Investigator of this study commented: "Based on my clinical trial work in Stemedica's Ischemic Stroke trial, my experience to date with Stemedica's allogeneic ischemic tolerant mesenchymal stem cell product suggests that the product is first and foremost safe and secondarilyhas the potential to produce unparalleled medical benefits."
About Stemedica Cell Technologies, Inc.Stemedica Cell Technologies, Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for ischemic stroke, and Alzheimer's Disease. Stemedica's cell are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California and can be found online atwww.stemedica.com.
Forward Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Media ContactStemedica Cell Technologies, Inc.Dave McGuiganEVP, Marketing & Business Developmentdmcguigan@stemedica.com+1 858-658-0910 x7203
SOURCE Stemedica Cell Technologies, Inc.
Read the rest here:
Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in...
- Arizona Oncology Cancer Center working with NexCore Group on new cancer treatment center - Yahoo Finance - October 13th, 2022
- Senate Passes 'Inflation Reduction Act' Which Will Likely Make Inflation Worse - Reason - August 14th, 2022
- Reds prospect rankings will shift after trade deadline acquisition of 10 players - The Athletic - August 5th, 2022
- Stem Cell Therapy Pros and Cons - Arizona Pain and Spine Institute - July 11th, 2022
- Bone Anatomy | Ask A Biologist - Arizona State University - July 11th, 2022
- No, "Top Gun" isn't an anti-woke success story, but rather a tribute to aging Tom Cruise and balls - Salon - June 4th, 2022
- Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit - Lewiston Sun Journal - June 4th, 2022
- BioEclipse Therapeutics Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer... - May 2nd, 2022
- Right to Try 2.0: Ahwatukee family pushes for proposed law after getting medical treatment abroad - FOX 10 News Phoenix - April 6th, 2022
- Inside the real life Noahs Ark designed to save mankind after the apocalypse with a back up vault on t... - The US Sun - January 5th, 2022
- Human Embryonic Stem Cells - Arizona State University - November 22nd, 2021
- Mindy Kaling's 'The Sex Lives of College Girls' Is a Spot-On Depiction of College - Glamour - November 22nd, 2021
- Bridging the gap between online and on campus - ASU Now - November 22nd, 2021
- Bacterial Infections Linked with Unapproved Stem Cell Treatments - Contagionlive.com - October 28th, 2021
- ASU professor researches origins of Alzheimers to find a cure - Eight, Arizona PBS - October 16th, 2021
- City of Hope to Accelerate Blood Cancer Research Through a Transformational Gift from Leukemia Survivor James Belardi and His Wife Leslie Belardi -... - October 5th, 2021
- Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy... - August 18th, 2021
- Jim McMahon broke his neck playing for Vikings, and found out about it 17 years later - TwinCities.com-Pioneer Press - December 23rd, 2020
- Want to Know Where The Best Fall Colors Are in Your Area? Check Out This Interactive US Map - Good News Network - October 5th, 2020
- 'Were not your slaves': Alternative health providers bristle at warning letters about their coronavirus treatments - USA TODAY - September 4th, 2020
- Neogene precipitation, vegetation, and elevation history of the Central Andean Plateau - Science Advances - September 4th, 2020
- Research Roundup: Lasting Immunity to COVID-19 and More - BioSpace - August 21st, 2020
- What in the world is 'Project Carpaccio' and which Israeli company is doing business in Abu Dhabi? - CTech - August 21st, 2020
- Viruses have big impacts on ecology and evolution as well as human health - The Economist - August 21st, 2020
- Encouraging News About Coronavirus Immunity | In the Pipeline - Science Magazine - August 21st, 2020
- Scientists are seeing signs of lasting immunity to COVID-19, among survivors with even mild infections - Firstpost - August 21st, 2020
- Studies show positive signs of strong, lasting Covid-19 immunity - The Irish Times - August 21st, 2020
- Coronavirus vaccine will take time, so researchers are hunting for and finding promising new COVID-19 tre - OregonLive - April 6th, 2020
- Penn announces seven 2020 Thouron Award winners - Penn: Office of University Communications - February 24th, 2020
- Unlocking The Secrets Of DNA Help Researchers Understand How to Slow Aging - YouAreUNLTD - January 9th, 2020
- An ESPN reporter was diagnosed with HLH just before he died at age 34. What is it? - ABC15 Arizona - January 2nd, 2020
- 2020s visions: We'll get flying cars just before becoming software-based people - CNET - December 19th, 2019
- Man fights $4,600 surgery bill he was told insurance would cover - KGUN - December 8th, 2019
- Professor Recognized For Cardiac Regeneration Research - WPI News - December 8th, 2019
- Creative Medical Technology Holdings, Inc. Discusses CaverStem and Other Patented Technology with The Stock Day Podcast - Yahoo Finance - October 19th, 2019
- Bone marrow recipient comes face-to-face with CT donor for the first time - WTNH.com - October 19th, 2019
- Stem Cell Education Center - Stem Cell Treatment | Arizona ... - September 14th, 2019
- Stem Cell Therapy In Scottsdale Arizona | Regenerative ... - September 12th, 2019
- Stem Cell Therapy | Board Certified Orthopedic Surgeon ... - March 16th, 2019
- Stem Cell Lake Havasu City Arizona 86406 - March 8th, 2019
- Stem Cell Therapy for Cancer | Arizona Pain and Spine ... - December 18th, 2018
- Stem Cells | Arizona Pain Specialists - Scottsdale ... - December 11th, 2018
- Arizona Pain Regenerative Institute - Arizona Pain Specialists - December 5th, 2018
- Stem Cell Therapy Phoenix Arizona | Desert Health Specialists - December 4th, 2018
- Southwest Spine and Sports - Pain Management Doctor Arizona - September 24th, 2018
- Celebration Stem Cell Centre - A private umbilical cord ... - August 12th, 2018
- Bone marrow transplant - Mayo Clinic - July 15th, 2018
- About Dr. Nabil Dib - June 27th, 2018
- Around the world - Bend Bulletin - August 30th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - KNAU Arizona Public Radio - August 30th, 2017
- BrainStorm Supports Commitment to ALS Patient Community with ... - Markets Insider - August 8th, 2017
- ASU grad students' lab skills help earn funding for cutting-edge biomedical research - Arizona State University - August 8th, 2017
- Will putting leeches on his face help this blind man see? - USA TODAY - August 8th, 2017
- Engineered Skin Cells Control Type 2 Diabetes in Mice: Study ... - Arizona Daily Star - August 8th, 2017
- 'Soft' side of bioengineering poised to make big impacts - Arizona State University - August 4th, 2017
- Tackling hard-to-treat cancers from every angle - Medical Xpress - June 21st, 2017
- ALS Research Forum | To Evaluate Stem Cell Therapies, Think ... - ALS Research Forum - June 20th, 2017
- New book by ASU researcher explores cancer's pervasive mysteries - Arizona State University - June 18th, 2017
- Arizona Supreme Court Clears Way For Adoption of American Indian Child by Non-Native Parents - Reason (blog) - June 15th, 2017
- Can We Cheat Death? US Firm Aims To Resurrect Brain-Dead People Using Stem Cells - International Business Times - June 11th, 2017
- The three cancers Jews need to worry about most and how to reduce the risks - Jewish Post - June 11th, 2017
- Patient-Centered Stem Cell Therapy Bill Passed by Texas Legislature - satPRnews (press release) - May 31st, 2017
- 6 Arizona young women are taking on the STEM gender gap - AZCentral.com - May 28th, 2017
- Scientists wary as Texas mulls allowing sale of unproven drugs - Texas Tribune - May 26th, 2017
- Scientists wary as Texas mulls allowing sale of unproven drugs - Bryan-College Station Eagle - May 24th, 2017
- ASU engineers envision 'guiding' body's cells to help improve health - Arizona State University - May 19th, 2017
- GV Gardeners: Sun-loving saguaro Southwest symbol | Sun Life ... - Sahuarita Sun (subscription) - May 19th, 2017
- Derek McCartney Named To Lott IMPACT Trophy Watch List - KKTV 11 News - May 18th, 2017
- Tucson Tech: University of Arizona startup advances living heart patch - Arizona Daily Star - May 15th, 2017
- Scientists uncover root of graying, thinning hair - Arizona Daily Star - May 15th, 2017
- GV Gardeners: Sun-loving saguaro Southwest symbol - Green Valley News - May 15th, 2017
- 7-year-old Hollis spread joy around U.S. After losing him to rare brain tumor, parents turn to finding cure - AZCentral.com - May 1st, 2017
- Young minds meet new technology at STEM-focused after-school program - USC News - April 19th, 2017
- Applications for Tissue Culture in Cannabis Growing: Part 1 - Cannabis Industry Journal (blog) - April 14th, 2017
- Yankees: James Kaprielian Getting Tommy John Surgery Out of the Way - Yanks Go Yard - April 14th, 2017
- Can Stem Cell 'Patch' Help Heart Failure? - Arizona Daily Star - April 9th, 2017
- Angels' focus is on defense - Reading Eagle - April 2nd, 2017
- Some restoration drama at the Big A as Dodgers top Angels, 3-1 - Los Angeles Times - April 1st, 2017
- Robert Clayton Robbins Top Choice for UA President - Arizona Public Media - March 10th, 2017
- R. William Funk Lands New Leader for University of Arizona - Hunt Scanlon Media (press release) - March 9th, 2017